Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tranexamic acid
Drug ID BADD_D02261
Description Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent.[L31883] It was first patented in 1957[A230108] and received its initial US approval in 1986.[L31858]
Indications and Usage Dunn CJ, Goa KL: Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999 Jun;57(6):1005-32.
Marketing Status Prescription; Discontinued
ATC Code B02AA02
DrugBank ID DB00302
KEGG ID D01136
MeSH ID D014148
PubChem ID 5526
TTD Drug ID D05HXX
NDC Product Code 12079-2001; 71052-166; 42571-314; 51754-0108; 67457-197; 71335-1957; 69918-301; 60505-6169; 70860-400; 0591-3720; 63629-8838; 67850-041; 50090-5072; 0013-1114; 51552-0513; 38779-3211; 42571-189; 49452-7877; 67850-042; 81999-0001; 43066-008; 72485-107; 68382-891; 39822-1000; 55150-188; 72611-760; 50090-4530; 49452-7876; 12848-1004; 71335-1981; 70121-1398; 51662-1532; 65388-0156; 61990-0611; 63323-563; 65145-106; 23155-166; 38779-2794; 81284-611; 70771-1085; 73309-178; 57218-951; 63629-8599; 51927-0022; 63759-0038; 62991-3131; 69918-300; 17478-017; 0517-0960; 81284-612; 17478-018; 62559-265; 68083-160; 55566-2110; 23155-524
Synonyms Tranexamic Acid | AMCHA | trans-4-(Aminomethyl)cyclohexanecarboxylic Acid | t-AMCHA | AMCA | Anvitoff | Cyklokapron | Ugurol | KABI 2161 | Spotof | Transamin | Amchafibrin | Exacyl
Chemical Information
Molecular Formula C8H15NO2
CAS Registry Number 701-54-2
SMILES C1CC(CCC1CN)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Polyuria20.02.03.002--Not Available
Pruritus23.03.12.001--
Pulmonary embolism24.01.06.001; 22.06.02.0010.242904%Not Available
Pulmonary oedema22.01.03.003; 02.05.02.003--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Renal cortical necrosis24.04.11.002; 20.01.07.0060.003727%Not Available
Renal failure20.01.03.0050.013046%Not Available
Renal infarct24.04.11.003; 20.01.07.0080.014288%Not Available
Respiratory distress22.02.01.0120.014288%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.003727%
Restlessness19.11.02.002; 17.02.05.0210.014288%
Retinal artery occlusion24.01.07.003; 06.10.01.0050.028577%Not Available
Seizure17.12.03.0010.292914%
Sinus congestion22.04.06.001--Not Available
Sinus headache17.14.01.002; 22.02.05.023--
Sinusitis22.07.03.007; 11.01.13.005--
Spinal fracture15.08.05.001; 12.04.04.0020.014288%
Status epilepticus17.12.03.0050.050010%Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.0200.028577%
Subarachnoid haemorrhage24.07.04.004; 17.08.01.010; 12.01.10.0110.003727%Not Available
Swelling08.01.03.015--Not Available
Swelling face10.01.05.018; 23.04.01.0180.028577%Not Available
Swollen tongue10.01.05.015; 23.04.01.014; 07.14.02.0030.014288%Not Available
Syncope24.06.02.012; 17.02.04.008; 02.01.02.0080.021433%
Tachycardia02.03.02.0070.064298%Not Available
Tension headache17.14.01.004--Not Available
Thrombocytopenia01.08.01.0020.035721%Not Available
Thrombosis24.01.01.0060.020501%Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.0060.005591%
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages